172 related articles for article (PubMed ID: 9156364)
1. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
Jones RL; Qian YM; Wise H; Wong HN; Lam WL; Chan HW; Yim AP; Ho JK
J Cardiovasc Pharmacol; 1997 Apr; 29(4):525-35. PubMed ID: 9156364
[TBL] [Abstract][Full Text] [Related]
2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
[TBL] [Abstract][Full Text] [Related]
3. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
Seiler SM; Brassard CL; Federici ME; Romine J; Meanwell NA
Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064
[TBL] [Abstract][Full Text] [Related]
4. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.
Chow KB; Wong YH; Wise H
Br J Pharmacol; 2001 Dec; 134(7):1375-84. PubMed ID: 11724742
[TBL] [Abstract][Full Text] [Related]
5. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
Merritt JE; Brown AM; Bund S; Cooper DG; Egan JW; Hallam TJ; Heagerty AM; Hickey DM; Kaumann AJ; Keen M
Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
[TBL] [Abstract][Full Text] [Related]
6. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors.
Wise H; Qian YM; Jones RL
Eur J Pharmacol; 1995 May; 278(3):265-9. PubMed ID: 7589166
[TBL] [Abstract][Full Text] [Related]
7. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action.
Seiler SM; Brassard CL; Federici ME; Buchanan JO; Zavoico GB; Fleming JS; Meanwell NA
Thromb Res; 1994 Apr; 74(2):115-23. PubMed ID: 8029812
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.
Wise H
Prostaglandins Leukot Essent Fatty Acids; 1996 May; 54(5):351-60. PubMed ID: 8832764
[TBL] [Abstract][Full Text] [Related]
9. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
Meanwell NA; Romine JL; Rosenfeld MJ; Martin SW; Trehan AK; Wright JJ; Malley MF; Gougoutas JZ; Brassard CL; Buchanan JO
J Med Chem; 1993 Nov; 36(24):3884-903. PubMed ID: 7504734
[TBL] [Abstract][Full Text] [Related]
10. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon.
Rudd JA; Qian Ym; Tsui KK; Jones RL
Br J Pharmacol; 2000 Feb; 129(4):782-90. PubMed ID: 10683203
[TBL] [Abstract][Full Text] [Related]
11. Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS; Zavoico GB
J Med Chem; 1993 Nov; 36(24):3871-83. PubMed ID: 8254619
[TBL] [Abstract][Full Text] [Related]
12. Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse.
Chan KM; Jones RL
J Cardiovasc Pharmacol; 2004 Jun; 43(6):795-807. PubMed ID: 15167273
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting prostacyclin receptor agonist efficacy in different cell types.
Kam Y; Chow KB; Wise H
Cell Signal; 2001 Nov; 13(11):841-7. PubMed ID: 11583920
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.
Dong YJ; Jones RL; Wilson NH
Br J Pharmacol; 1986 Jan; 87(1):97-107. PubMed ID: 2420404
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Benyahia C; Boukais K; Gomez I; Silverstein A; Clapp L; Fabre A; Danel C; Leséche G; Longrois D; Norel X
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():48-55. PubMed ID: 23850788
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
[TBL] [Abstract][Full Text] [Related]
17. The mechanisms of enhancement and inhibition of field stimulation responses of guinea-pig vas deferens by prostacyclin analogues.
Tam FS; Chan K; Borreau JP; Jones RL
Br J Pharmacol; 1997 Aug; 121(7):1413-21. PubMed ID: 9257922
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.
Li Y; Connolly M; Nagaraj C; Tang B; Bálint Z; Popper H; Smolle-Juettner FM; Lindenmann J; Kwapiszewska G; Aaronson PI; Wohlkoenig C; Leithner K; Olschewski H; Olschewski A
Am J Respir Cell Mol Biol; 2012 Mar; 46(3):372-9. PubMed ID: 22021335
[TBL] [Abstract][Full Text] [Related]
19. Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Trehan AK; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS
Drug Des Discov; 1994 Jan; 11(1):73-89. PubMed ID: 7520762
[TBL] [Abstract][Full Text] [Related]
20. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
